These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22495647)

  • 1. [Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine].
    Tomberli B; Girolami F; Coppini R; Ferrantini C; Rossi A; Cecchi F; Olivotto I
    G Ital Cardiol (Rome); 2012 Apr; 13(4):297-303. PubMed ID: 22495647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypertrophic cardiomyopathy with restrictive pathophysiology: is there a role for cardiopulmonary exercise testing?].
    Correale M; Passero T; Totaro A; Di Biase M
    G Ital Cardiol (Rome); 2012 Dec; 13(12):861; author's reply p.861. PubMed ID: 23196690
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey].
    Reith S; Klues HG
    Z Kardiol; 2003 Apr; 92(4):283-93. PubMed ID: 12707787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of symptoms in hypertrophic cardiomyopathy.
    Fifer MA; Vlahakes GJ
    Circulation; 2008 Jan; 117(3):429-39. PubMed ID: 18212300
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
    Athauda-Arachchi P; Lang C
    Cardiovasc Ther; 2012 Aug; 30(4):e210-1. PubMed ID: 21884008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New trends in treatment of hypertrophic cardiomyopathy.
    Hagège AA; Desnos M
    Arch Cardiovasc Dis; 2009 May; 102(5):441-7. PubMed ID: 19520330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.
    Nanda S; Levin V; Martinez MW; Freudenberger R
    Pacing Clin Electrophysiol; 2010 Dec; 33(12):e119-20. PubMed ID: 20345626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myectomy for hypertrophic obstructive cardiomyopathy.
    McRae ME
    Can J Cardiovasc Nurs; 2007; 17(2):22-30. PubMed ID: 17583317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apical myectomy: a new surgical technique for management of severely symptomatic patients with apical hypertrophic cardiomyopathy.
    Schaff HV; Brown ML; Dearani JA; Abel MD; Ommen SR; Sorajja P; Tajik AJ; Nishimura RA
    J Thorac Cardiovasc Surg; 2010 Mar; 139(3):634-40. PubMed ID: 20176208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does myectomy convey survival benefit in hypertrophic cardiomyopathy?
    Woo A; Rakowski H
    Heart Fail Clin; 2007 Jul; 3(3):275-88. PubMed ID: 17723936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.
    Valeti US; Nishimura RA; Holmes DR; Araoz PA; Glockner JF; Breen JF; Ommen SR; Gersh BJ; Tajik AJ; Rihal CS; Schaff HV; Maron BJ
    J Am Coll Cardiol; 2007 Jan; 49(3):350-7. PubMed ID: 17239717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of dilated-hypokinetic hypertrophic cardiomyopathy by biventricular cardiac pacing.
    Ashrafian H; Mason MJ; Mitchell AG
    Europace; 2007 Jan; 9(1):50-4. PubMed ID: 17224423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiomyopathies in adolescents: dilated, hypertrophic, and restrictive.
    Shaddy RE
    Adolesc Med; 2001 Feb; 12(1):35-45. PubMed ID: 11224021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
    Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pacemaker stimulation in dilated and hypertrophic myocardiopathies: should its use be stratified?].
    López Meneses M; Olvera Cruz S
    Arch Cardiol Mex; 2002; 72 Suppl 1():S117-21. PubMed ID: 12001828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual chamber pacing in patients with hypertrophic obstructive cardiomyopathy: a case study.
    Wackowski CA; Bierman PQ
    Am J Crit Care; 1995 Mar; 4(2):165-8. PubMed ID: 7749450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy].
    Gao YC; Li Y; Han ZH; Zhang XL; Zhao H; Jiang TY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Apr; 35(4):333-6. PubMed ID: 17711659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
    Sossalla S; Maier LS
    Pharmacol Ther; 2012 Mar; 133(3):311-23. PubMed ID: 22133843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertrophic cardiomyopathy with restrictive phenotype and myocardial crypts.
    Cannavale A; Ordovás KG; Rame EJ; Higgins CB
    J Thorac Imaging; 2010 Nov; 25(4):W121-3. PubMed ID: 20463612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.